Beijing
AstraZeneca’s China woes recede as focus shifts to upcoming readouts
$2.5 billion R&D investment in Beijing, Global strategic R&D center, China legal issues resolution, Biotech partnerships, Manufacturing expansion, $8 million potential fine, FibroGen China acquisition
Sanofi Invests €1 Billion in Beijing to Enhance Insulin Production Capacity
Sanofi, insulin production, Beijing, investment, pharmaceutical industry